Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter

Overview

Journal Crit Care Explor

Specialty Critical Care

Date 2020 Aug 9

PMID 32766569

Citations 19

Authors

Stephen W Olson

James D Oliver

Jacob Collen

Jessica Bunin

Todd D Gleeson

Brian E Foster

Mark P Simmons

Hua W Chen

Jennifer B Ficke

Tara E Brown

Mark T Nau

Brennan R Cebula

Jan Kielstein

Kevin K Chung

Affiliations

Soon will be listed here.

Abstract

Data Sources: The first two patients in the United States treated with the novel Seraph-100 device. These cases were reviewed by the Food and Drug Administration prior to granting an emergency use authorization for treatment of coronavirus disease 2019.

Study Selection: Case series.

Data Extraction: Vasopressor dose, mean arterial pressure, temperature, interleukin-6, C-reactive protein, and other biomarker levels were documented both before and after Seraph-100 treatments.

Data Synthesis: Vasopressor dose, temperature, interleukin-6, and C-reactive protein levels declined after Seraph-100 treatments. Severe acute respiratory syndrome coronavirus 2 viremia was confirmed in the one patient tested and cleared by the completion of treatments.

Conclusions: Seraph-100 use may improve hemodynamic stability in coronavirus disease 2019 cases requiring mechanical ventilation and vasopressor support. These findings warrant future study of a larger cohort with the addition of mortality and total hospital day outcomes.

Citing Articles

Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy.

Shishido S, Suresh D, Courcoubetis G, Ye B, Lin E, Mason J BJC Rep. 2024; 2(1):47.

PMID: 39516545 PMC: 11524105. DOI: 10.1038/s44276-024-00069-3.

Successful Repeated Use of a Pathogen Adsorbing Biomimetic Device for the Adjunct Treatment of a SARS-CoV-2 Reinfection and Subsequent Infections with Different Multiresistant Bacteria.

Okioma R, Soki K, Hay A, Kielstein J Case Rep Nephrol Dial. 2024; 14(1):171-177.

PMID: 39474253 PMC: 11521500. DOI: 10.1159/000541422.

The Seraph 100 Microbind Affinity Blood Filter Does Not Alter Levels of Circulating or Mucosal Antibodies in Critical COVID-19 Patients.

Conner T, Vir P, Laing E, Stewart I, Mitre E, Pratt K Antibodies (Basel). 2024; 13(3).

PMID: 39189236 PMC: 11348046. DOI: 10.3390/antib13030065.

AKI in Adults with COVID-19 Infection: Mechanisms of Development and Role of Blood Filtration Devices in Treatment.

Hu J, Raina M, Mehta I, Sethi S, Soundararajan A, Bansal S Indian J Nephrol. 2024; 33(6):411-419.

PMID: 38174296 PMC: 10752394. DOI: 10.4103/ijn.ijn_51_23.

Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility.

Damianaki A, Stambolliu E, Alexakou Z, Petras D Kidney Res Clin Pract. 2023; 42(3):298-311.

PMID: 37098671 PMC: 10265212. DOI: 10.23876/j.krcp.22.223.

References

Villa G, Zaragoza J, Sharma A, Neri M, De Gaudio A, Ronco C . Cytokine removal with high cut-off membrane: review of literature. Blood Purif. 2014; 38(3-4):167-73. DOI: 10.1159/000369155. View

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

Schmidt J, Eden G, Seffer M, Winkler M, Kielstein J . elimination of anti-infective drugs by the Seraph 100 Microbind affinity blood filter. Clin Kidney J. 2020; 13(3):421-424. PMC: 7367135. DOI: 10.1093/ckj/sfaa063. View

Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X . Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect. 2020; 9(1):469-473. PMC: 7054964. DOI: 10.1080/22221751.2020.1732837. View

Richardson S, Hirsch J, Narasimhan M, Crawford J, McGinn T, Davidson K . Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020; 323(20):2052-2059. PMC: 7177629. DOI: 10.1001/jama.2020.6775. View

Kim S, Park S, Cho S, Cha R, Jee H, Kim G . Viral RNA in Blood as Indicator of Severe Outcome in Middle East Respiratory Syndrome Coronavirus Infection. Emerg Infect Dis. 2016; 22(10):1813-6. PMC: 5038397. DOI: 10.3201/eid2210.160218. View

Ronco C, Bagshaw S, Bellomo R, Clark W, Husain-Syed F, Kellum J . Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation. Blood Purif. 2020; 50(1):17-27. PMC: 7270067. DOI: 10.1159/000508125. View

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

Zhou F, Peng Z, Murugan R, Kellum J . Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med. 2013; 41(9):2209-20. PMC: 3758418. DOI: 10.1097/CCM.0b013e31828cf412. View

10.

Seffer M, Cottam D, Forni L, Kielstein J . Heparin 2.0: A New Approach to the Infection Crisis. Blood Purif. 2020; 50(1):28-34. PMC: 7445380. DOI: 10.1159/000508647. View

11.

Hung I, Cheng V, Wu A, Tang B, Chan K, Chu C . Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004; 10(9):1550-7. PMC: 3320271. DOI: 10.3201/eid1009.040058. View

12.

Dreher M, Kersten A, Bickenbach J, Balfanz P, Hartmann B, Cornelissen C . The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS. Dtsch Arztebl Int. 2020; 117(16):271-278. PMC: 7171478. DOI: 10.3238/arztebl.2020.0271. View

13.

Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M . Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open. 2014; 4(1):e003536. PMC: 3902195. DOI: 10.1136/bmjopen-2013-003536. View

14.

Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y . Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(8):1937-1942. PMC: 7184354. DOI: 10.1093/cid/ciaa449. View

15.

Liu Y, Yan L, Wan L, Xiang T, Le A, Liu J . Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020; 20(6):656-657. PMC: 7158902. DOI: 10.1016/S1473-3099(20)30232-2. View

16.

Bellomo R, Tetta C, Ronco C . Coupled plasma filtration adsorption. Intensive Care Med. 2003; 29(8):1222-8. DOI: 10.1007/s00134-003-1796-x. View

17.

McMichael T, Currie D, Clark S, Pogosjans S, Kay M, Schwartz N . Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med. 2020; 382(21):2005-2011. PMC: 7121761. DOI: 10.1056/NEJMoa2005412. View

18.

Wang W, Fang C, Chen H, Yang C, Chen Y, Chen M . Detection of severe acute respiratory syndrome coronavirus RNA in plasma during the course of infection. J Clin Microbiol. 2005; 43(2):962-5. PMC: 548103. DOI: 10.1128/JCM.43.2.962-965.2005. View

19.

Young B, Ong S, Kalimuddin S, Low J, Tan S, Loh J . Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020; 323(15):1488-1494. PMC: 7054855. DOI: 10.1001/jama.2020.3204. View

20.

Zhang W, Du R, Li B, Zheng X, Yang X, Hu B . Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020; 9(1):386-389. PMC: 7048229. DOI: 10.1080/22221751.2020.1729071. View